Long-term Survival with a Rare Advanced Primary Gastrointestinal Malignant Melanoma Treated with Laparoscopic Surgery/Immune Checkpoint Inhibitor

Acta Med Okayama. 2021 Apr;75(2):231-238. doi: 10.18926/AMO/61906.

Abstract

Targeted therapies for malignant melanoma have improved patients' prognoses. A primary gastrointestinal malignant melanoma is very rare, with no standard treatment strategy. We treated a 78-year-old Japanese female with advanced primary gastrointestinal melanoma of the descending colon and gallbladder. We administered a multidisciplinary treatment: surgical resection of the descending colon and gallbladder tumors, resection of the metastatic lymph nodes behind the pancreas head, and immune checkpoint antibody-blockade therapy (nivolumab) for ~4 years. PET/CT demonstrated no recurrent lesion for > 3 years. Multidisciplinary therapies (e.g., surgery, chemotherapy, radiotherapy, target therapy, and immune checkpoint antibody-blockade therapy) can successfully treat primary gastrointestinal malignant melanoma.

Keywords: immune checkpoint antibody-blockade inhibitor; laparoscopic surgery; primary gastrointestinal melanoma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Female
  • Gastrointestinal Neoplasms / therapy*
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Laparoscopy / methods*
  • Melanoma / therapy*
  • Treatment Outcome

Substances

  • Immune Checkpoint Inhibitors